Clinicopathologic profile of gestational trophoblastic disease

Wiener Klinische Wochenschrift

Volumn 115, Issue 1-2, 2003, Pages 29-35

  Jelincic, Darko ^a,d   Hudelist, Gernot ^a   Singer, Christian Fridolin ^a   Bauer, Margit ^b   Horn, Lars Christian ^c   Bilek, Karin ^c   Czerwenka, Klaus ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C erbB 2 amplification expression; Clinicopathologic profile; DNA content; Gestational trophoblastic disease; Karyotype

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PROTEIN P185; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CHORIOCARCINOMA; CLINICAL ARTICLE; DISEASE MARKER; DNA CONTENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; KARYOTYPE 46,XY; LIVER METASTASIS; LUNG METASTASIS; ONCOGENE C ERB; PLOIDY; POLYMERASE CHAIN REACTION; PREGNANCY; REMISSION; RISK ASSESSMENT; SEX CHROMOSOME; TROPHOBLASTIC DISEASE;

EID: 0037473891     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03040269     Document Type: Article

References (38)

1. Genest DR, Laborde O, Berkowitz RS, Goldstein DP, Bernstein MR, Lage J (1991) A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-1990): histologic grade lacks prognostic significance. Obstet Gynecol 78: 402-408
2. Hertig A, Sheldon W (1947) Hydatidiform mole: a pathologico-clinical correlation of 200 cases. Am J Obstet Gynecol 53: 14-20
3. Elston CW, Bagshawe KD (1972) The value of histological grading in the management of hydatidiform mole. J Obstet Gynaecol Br Commonwealth 79: 717-724
4. Fukunga M (2000) Early partial hydatidiform mole: prevalence, histopathology, DNA ploidy, and persistence rate. Virchows Arch 437: 180-184
5. Barkley IDR, Dabbach L, Babiak J, Poppema S (1993) DNA analysis (ploidy) of molar pregnancies with image analysis on paraffin tissue sections. Am J Clin Pathol 100: 451-455
6. Cheville JC, Greiner T, Robinson RA, Benda JA (1995) Ploidy analysis by flow cytometry and fluorescence in situ hybridization in hydropic placentas and gestational trophoblastic disease. Hum Pathol 26: 753-757
7. Lage JM (1991) Flow cytometric analysis of DNA content in gestational trophoblastic disease. J Reprod Med 36: 31-35
8. Lage JM, Mark SD, Roberts DJ, Goldstein DP, Bernstein MR, Berkowitz RS (1992) A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol 79: 403-410
9. Mark HGL, Grollino MG, Sulaiman RA, Lathrop JC (1995) Fluorescent in situ hybridization assessment of chromosome copy number in gestational trophoblastic disease. Ann Clin Lab Sci 25: 291-296
10. Davis JR, Kerrigan DP, Way DL, Weiner SA (1987) Partial hydatidiform moles: DNA-content and course. Am J Obstet Gynecol 157: 969-997
11. Mutter GL, Pomponio RJ, Berkowitz RS, Genest DR (1993) Sex chromosome composition of complete hydatidiform moles: relationship to metastasis. Am J Obstet Gynecol 168: 1547-1551
12. Wolf N, Lage JM (1995) Genetic analysis of gestational trophoblastic disease: a review. Semin Oncol 22: 113-120
13. Schammel DP, Bocklage T (1996) p53, PCNA, and Ki-67 in hydropic molar and nonmolar placentas: An immunhistochemical study. Int J Gynecol Pathol 15: 158-166
14. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS (1998) p53, p21, Rb and mdm2 oncoproteins expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43: 119-127
15. Halperin R, Peller S, Sandbank J, Bukovsky I, Schneider D (2000) Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta 21: 58-62
16. Cameron B, Gown AM, Tamimi HK (1994) Expression of c-erbB-2 oncogene product in persistent gestational trophoblastic disease. Am J Obstet Gynecol 170: 1616-1622
17. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS (1998) C-myc, c-erbB-2, c-fms and bcl-2 oncoproteins expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 43: 101-110
18. Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS (2000) Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecologic Oncology 77: 389-393
19. Frye RA, Benz C, Liu E (1989) Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4: 1153-1157
20. Czerwenka K, Yongxian L, Heuss F (1995) Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic and malignant endometria. Int J Gynecol Pathol 14: 98-106
21. Hedley DW, Fridlander ML, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA-content of paraffin-embedded material using flow cytometry. J Histochem Cytochem 31: 1333-1335
22. Vassilakos P, Riotton G, Kaji T (1977) Hydatidiform mole: two entities. Am J Obstet Gynecol 127: 167-170
23. Wright C, Nicholson S, Angus B, et al (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121
24. Slamon DJ, Clark GM, Wong CG (1987) Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235: 177-182
25. Slamon DJ, Clark GM, Wong SG (1989) Studies of HER-2/neu protooncogene in human breast and ovarian cancer. Science 224: 701-712
26. Berchuck A, Kamel A, Whitaker R (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
27. Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p 185. Cell 45: 649-657
28. Mazur MT, Kurman RJ (1994) Gestational trophoblastic disease and related lesions. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract. Springer, New York Berlin Heidelberg, pp 1049-1093
29. Carter P (1996) Targeting the product of the HER2/neu protooncogene for therapy. In: Calvo F, Crépin M, Magdelenat H (eds) Breast cancer. Advances in biology and therapeutics. John Libbbey Eurotext, Montrouge London Rome, pp 139-146
30. Wake N, Tanaka K, Chapman V, Matsui S, Sandberg AA (1981) Chromosomes and cellular origin of choriocarcinoma. Cancer Res 41: 3137
31. Wake N, Seki T, Fujita H, et al (1984) Malignant potential of homozygous and heterozygous complete moles. Cancer Res 44: 1226
32. Fisher RA, Lawler SD (1984) Heterozygous complete hydatidiform moles: do they have a worse prognosis than homozygous complete moles? Lancet 2: 51
33. Van de Kaa CA, Hanselaar AG, Hopman AH, et al (1993) DNA cytometric and interphase cytogenetic analyses of paraffin-embedded hydatidiform moles and hydropic abortions. J Pathol 170: 229-235
34. Van de Kaa CA, Schijf CPT, de Wilde PCM, de Leeuw H, Gemmink JH, Robben JCM, Vooijs PG (1996) Persistant gestational trophoblastic disease: DNA image cytometry and interphase cytogenetics have limited predictive value. Mod Pathol 9: 1007-1014
35. Martin DA, Sutton GP, Ulbright TM, Sledge GW, Stehmann FB, Ehrlich CE (1989) DNA-content as prognostic index in gestational trophoblastic neoplasia. Gynecol Oncol 34: 383-388
36. Sugimori H, Kashimura Y, Kashimura M, Taki I (1978) Nuclear DNA-content of trophoblastic tumors. Acta Cytol 22:542-547
37. Fukunaga M, Ushigome S, Fukunaga M, Sugishita M (1993) Application of flow cytometry in diagnosis of hydatidiform moles. Mod Pathol 6: 353-358
38. Hemming JD, Quirke P, Womack C, et al (1988) Flow cytometry in persistent trophoblastic disease. Placenta 9: 615-621